Approximately 900 tick species exist worldwide, parasitizing a broad array of mammals, including humans, and thereby playing a significant role in the transmission of infectious diseases (1). In the United States, tick-borne diseases are generally seasonal and geographically distributed. They occur mostly during the spring and summer but can occur throughout the year.
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Amsden, J. R., Warmack, S., and Gubbins, P. O. (2005) Tick-borne bacterial, rickettsial, spirochetal, and protozoal infectious diseases in the United States: a comprehensive review, Pharmacotherapy, 25(2), 191–210.
Parola, P. and Raoult, D. (2001) Ticks and tickborne bacterial diseases in humans: an emerging infectious threat, Clin. Infect. Dis., 32, 897–928.
Parola, P. and Raoult, D. (2001) Tick-borne bacterial diseases emerging in Europe, Clin. Microbiol. Infect., 7(2), 80–83.
Centers for Disease Control (2007) Lyme disease—United States, 2003–2005, Morb. Mortal. Wkly Rep., 55(23), 573–576.
Steere, A. C., Coburn, J., and Glickstein, L. (2004) The emergence of Lyme disease, J. Clin. Invest., 113(4), 1093–1101.
Schwan, T. G. and Piesman, J. (2000) Temporal changes in outer surface proteins A and C of the Lyme disease-associated spirochete Borrelia burgdorferi, during the chain of infections in ticks and mice, J. Clin. Microbiol., 38(1), 382–388.
Revel, A. T., Blevins, J. S., Almazán, C., Neil, L., Kocan, K. M., de la Fuente, J., Hagman, K. E., and Norgard, M. V. (2005) bptA (bbe16) is essential for the persistence of the Lyme disease spirochete, Borrelia burgdorferi, in its natural tick vector, Proc. Natl. Acad. Sci. U.S.A., 102(19), 6972–6977.
Latov, N., Wu, A. T., Chin, R. L., Sander, H. W., Alaedini, A., and Brannagan, T. H., III (2004) Neuropathy and cognitive impairment following vaccination with the OspA protein of Borrelia burgdorferi, J. Peripheral Nervous System, 9, 165–167.
Wormser, G. P., Nadelman, R. B., Dattwyler, R. J., Dennis, D. T., Shapiro, E. D., Steer, A. C., Rush, T. J., Rahn, D. W., Coyle, P. K., Persing, D. H., Fish, D., and Luft, B. J. (2000) Practice guidelines for the treatment of Lyme disease, Clin. Infect. Dis., 31(Suppl. 1), S1–S14.
Marques, A. R., Martin, D. S., and Phillipp, M. T. (2002) Evaluation of the C6 peptide enzyme-linked immunosorbent assay for individuals vaccinated with the recombinant OspA vaccine, J. Clin. Microbiol., 40(7), 2591–2593.
Burgdorfer, W., Barbour, A. G., Hayes, S. F., Benach, J. L., Grunwaldt, E., and Davis, J. P. (1982) Lyme disease—a tick-borne spirochete? Science, 216, 1317–1319.
Marques, A. R., Weir, S. C., Fahle, G. A., and Fischer, S. H. (2000) Lack of evidence of Borrelia involvement in Alzheimer’s disease, J. Infect. Dis., 182, 1006–1007.
Klempner, M. S., Hu, L. T., Evans, J., Schmid, C. H., Johnson, G. M., Trevino, R. P., Norton, D., Levy, L., Wall, D., McCall, J., Kosinski, M., and Weinstein, A. (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease, N. Engl. J. Med., 354(2), 85–92.
Kaplan, R. F., Trevino, R. B., Johnson, G. M., Levy, L., Dornbush, R., Hu, L. T., Evans, J., Weinstein, A., Schmid, C. H., and Klempner, S. S. (2003) Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology, 60(12), 1916–1922.
Krupp, L. B., Hyman, L. G., Grimson, R., Coyle, P. K., Melville, P., Ahnn, S., Dattwyler, R., and Chandler, B. (2003) Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial, Neurology, 60(12), 1923–1930.
Pachner, A. R., Dail, D., Bai, Y., Sondey, M., Pak, L., Narayan, K., and Cadavid, D. (2004) Genotypes determine phenotype in experimental Lyme disease, Ann. Neurol., 56(3), 361–370.
Pachner, A. R., Dail, D., Narayan, K., Dutta, K., and Cadavid, D. (2002) Increased expression of B-lymphocyte chemoattractant but not pro-inflammatory cytokines, in muscle tissue in rhesus chronic Lyme borreliosis, Cytokine, 19(6), 297–307.
Rupprecht, T. A., Pfister, H. W., Angele, B., Kastenbauer, S., Wilske, B., and Koedel, U. (2005) The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis, Neurology, 65(3), 448–450.
Bockenstedt, L. K., Mao, J., Hodzic, E., Barthold, S. W., and Fish, D. (2002) Detection of attenuated, noninfectious spirochetes of Borrelia burgdorferi-infected mice after antibiotic treatment, J. Infect. Dis., 186(6), 1430–1437.
Hemmer, B., Gran, B., Zhao, Y., Marques, A., Pascal, J., Tzou, A., Kondo, T., Cortese, I., Bielekova, B., Straus, S. E., McFarland, H. F., Houghten, R., Simon, R., Pinilla, C., and Martin, R. (1999) Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease, Nat. Med., 5, 1375–1382.
Alaedini, A. and Latov, N. (2005) Antibodies against OspA epitopes of Borrelia burgdorferi cross-react with neural tissue, J. Neuroimmunol., 159(1–2), 192–195.
Raveche, E. S., Schutzer, S. E., Fernandes, H., Bateman, H., McCarthy, B. A., Nickell, S. P., and Cunningham, M. W. (2005) Evidence of Borrelia autoimmunity-induced component of Lyme carditis and arthritis, J. Clin. Microbiol., 43, 850–856.
Benvenga, S., Guarniei, F., Vaccaro, M., Santarpia, L., and Trimarchi, F. (2004) Homologies betwen proteins of Borrelia burgdorferi and thyroid autoantigens, Thyroid, 14(11), 964–966.
Klempner, M. S., Wormser, G. H., Wade, K., Trevino, R. P., Tang, K., Kaslow, R., and Schmid, C. (2005) A case-control study to examine HLA haplotype associations in patients with posttreatment chronic Lyme disease, J. Infect. Dis., 192(6), 1010–1013.
Moro, M. H., Zegara-Moro, O. L., Bjornsson, J., Hofmeister, E. K., Bruinsma, E., Germer, J. J., and Persing, D. H. (2002) Increased arthritis severity in mice coinfected with Borrelia burgdorferi and Babesia microti, J. Infect. Dis., 186(3), 428–431.
Thomas, V., Anguita, J., Barthold, S. W., and Fikrig, E. (2001) Co-infection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis alters the murine immune responses, pathogen burden, and severity of Lyme arthritis, Infect. Immun., 69(5), 3359–3371.
Klempner, M. S. (2002) Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease, Vector Borne Zoonotic Dis., 2, 255–263.
Ge, Z., Feng, Y., Whary, M. T., Nambiar, P. R., Xu, S., Ng, V., Taylor, N. S., and Fox, J. G. (2005) Cytolethal distending toxin is essential for colonization of Helicobacter hepaticus in outbread Swiss Webster mice, Infect. Immun., 73(6), 3440–3467.
Liang, F. T., Jacobson, R. H., Straubinger, R. K., Grooters, A., and Philipp, M. T. (2000) Characterization of a Borrelia burgdorferi VlsE invariable region useful in canine Lyme disease serodiagnosis by enzyme-linked immunosorbent assay, J. Clin. Microbiol., 38(11), 4160–4166.
Klempner, M. S., Schmid, C. H., Hu, L., Steere, A. C., Johnson, G., McCloud, B., Noring, R., and Weinstein, A. (2001) Intralaboratory reliability of serologic and urine testing for Lime disease, Am. J. Med., 110(3), 217–219.
Rauter, C., Mueller, M., Diterich, I., Zeller, S., Hassler, D., Meergans, T., and Hartung, T. (2005) Critical evaluation of urine-based PCR assay for diagnosis of Lyme borreliosis, Clin. Diag. Lab. Immunol., 12(8), 910–917.
Fleming, R. V., Marques, A. R., Klempner, M. S., Schmid, C. H., Dally, L. G., Martin, D. S., and Phillipp, M. T. (2004) Pre-treatment and post-treatment assessment of the C6 test in patients with persistent symptoms and a history of Lyme borreliosis, Eur. J. Clin. Microbiol. Infect. Dis., 23(6), 615–618.
Mogilyansky, E., Loa, C. C., Adelson, M. E., Mordechai, E., and Tilton, R. C. (2004) Comparison of Western immunoblotting and the Lyme antibody test for laboratory detection of Lyme disease, Clin. Diag. Lab. Immunol., 11(5), 924–929.
Philipp, M. T., Wormser, G. P., Marques, A. R., Bittker, S., Martin, D. S., Nowakowski, J., and Dally, L. G. (2005) A decline in antibody titer occurs in successfully treated patients with culture-controlled early localized or early disseminated Lyme borreliosis, Clin. Diag. Lab. Immunol., 12(9), 1069–1074.
Marques, A. R., Hornung, R. L., Dally, L., and Philipp, M. T. (2005) Detection of immune complexes is not independent of detection of antibodies in Lyme disease patients and does not confirm active infection with Borrelia burgdorferi, Clin. Diag. Lab. Immunol., 12(9), 1036–1040.
Purcer, J. E., Lawrenz, M. B., Caimano, M. J., Howell, J. K., Radolf, J. D., and Norris, S. J. (2003) A plasmid-encoded nicotinamidase (PncA) is essential for infectivity of Borrelia burgdorferi in a mammalian host, Mol. Microbiol., 48(3), 753–764.
Brooks, C. S., Vuppala, S. R., Jett, A. M., and Akins, D. R. (2006) Identification of Borrelia burgdorferi outer surface protein, Infect. Immun., 74(1), 296–304.
Pal, U., Xin, L., Wang, T., Montgomery, R. R., Ramamoorthi, N., deSilva, A. M., Bao, F., Yang, X., Pypaert, M., Pradham, D., Kantor, F. S., Telford, S., Anderson, J. F., and Fikrig, E. (2004) TROSPA, and Ixodes scapularis receptor for Borrelia burgdorferi, Cell, 119(4), 457–468.
Tsao, J. I., Wootton, J. T., Binikis, J., Luna, M. G., Fish, D., and Barbour, A. G. (2004) An ecological approach to preventing human infection: vaccinating wild mouse reservoirs intervenes in the Lyme disease cycle, Proc. Natl. Acad. Sci. U.S.A., 101(52), 18159–18164.
Ramamoorthy, N., Narasimhan, S., Pal, U., Yang, X. F., Fish, D., Anguita, J., Norgard, M. V., Kantor, F. S., Anderson, J. F., Koski, R. A., and Fikrig, E. (2005) The Lyme disease agent exploits a tick protein to infect the mammalian host, Nature, 436, 573–577.
Brossard, M. and Wikel, S. K. (2004) Tick immunobiology, Parasitology, 129 (Suppl.), S161–S176.
Burke, G., Wikel, S. K., Spielman, A., Telford, S. R., McKay, K., Krause, P. Y., and the Tick-borne Infection Study Group (2005) Hypersensitivity to ticks and Lyme disease risk, Emerg. Infect. Dis., 11(1), 36–41.
Lathrop, S. L., Ball, R., Haber, P., Mootrey, G. T., Braun, M. M., Shadomy, S. V., Elllenberg, S. S., Chen, R. T., and Hayes, E. B. (2002) Adverse event reports following vaccination against Lyme disease: December 1998–July 2000, Vaccine, 20(11–12), 1603–1608.
Schekelhoff, M. R., Telford, S. R., and Hu, L. T. (2006) Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs, Vaccine, 24(11), 1949–1957.
Earnhart, C. G., Buckles, E. L., Dumler, J. S., and Marconi, R. T. (2005) Demonstration of OspC type diversity in invasive human Lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response, Infect. Immun., 73(12), 7869–7877.
Velegraki, M., Samonis, G., Eliopoulos, G. D., and Papadaki, H. (2007) Toll like receptors: molecular structure and functional role in innate and adaptive immunity, Haema, 10(1), 18–26.
Bockenstedt, L. K., Liu, N., Schwartz, I., and Fish, D. (2006) MyD88 deficiency enhances acquisition and transmission of Borrelia burgdorferi by Ixodes scapularis ticks, Infect. Immun., 74(4), 2154–2160.
Centers for Disease Control (2006) Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spoted fever, ehrlichioses, and anaplasmosis—United States, (2006), Morb. Mortal. Wkly Rep., 55(RR-4), 1–27.
Andersson, S. G. E. (2004) Obligate intracellular pathogens. In: Microbial Genomes (Fraser, C. M., Read, T. D., and Nelson, K. E., eds.), Humana Press, Totowa, NJ, pp. 291–308.
Tillier, E. R. M. and Collins, R. A. (2000) Genome rearrangement by replication-directed translocation, Nature, 26, 195–197.
Walker, D. H. and Sexton, D. J. (1999) Rickettsia rickettsii. In: Antimicrobial Therapy and Vaccines (Yu, V. L., Merigan, T. C., Jr., and Barriere, S. L., eds.), Williams 8 Wilkins, Baltimore, pp. 562–568.
Smith Sendev, A. E., Sehdev, P. S., Jacobs, R., and Dumler, J. S. (2002) Human monocytic ehrlichiosis presenting as acute appendicitis during pregnancy, Clin. Infect. Dis., 35, e99–e102.
Walker, D. H. and Raoult, D. (2005) Rickettsia rickettsii and other spotted fever group Rickettsiae (Rocky Mountain spotted fever and other spotted fevers). In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease, 6th ed., Churchill Livingstone, Philadelphia, pp. 2287–2295.
Holman, R. C., Paddock, C. D., Curns, A. T., Krebs, J. W., McQuiston, J. H., and Childs, J. E. (2001) Analysis of risk factors for fatal Rocky Mountain spotted fever: evidence for superiority of tetracyclines for therapy, J. Infect. Dis., 184, 1437–1444.
Bakken, J. S., Krueth, J., Wilson-Nordskog, C., Tilden, R. L., Asanovich, K., and Dumler, J. S. (1996) Clinical and laboratory characteristics of human granulocytic ehrlichiosis, J. Am. Med. Assoc., 275, 199–205.
Brouqui, P. and Raoult, D. (1992) In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis, Antimicrob. Agents Chemother., 36, 2799–2803.
Treadwell, T. A., Holman, R. C., Clarke, M. J., Krebs, J. W., Paddock, C. D., and Childs, J. E. (2000) Rocky Mountain spoted fever in the United States, 1993–1996, Am. J. Trop. Med., 63, 21–26.
Archibald, L. K. and Sexton, D. J. (1995) Long-term sequelae of Rocky Mountain spotted fever, Clin. Infect. Dis., 20, 1122–1125.
Bakken, J. S. and Dumler, J. S. (2000) Human granulocytic ehrlichiosis, Clin. Infect. Dis., 31, 554–560.
Fishbein, D. B., Dawson, J. E., and Robinson, L. E. (1994) Human ehrlichiosis in the United States, 1985 to 1990, Ann. Intern. Med., 120, 736–743.
Paddock, C. D. and Childs, J. E. (2003) Ehrlichia chaffeensis: a prototypical emerging pathogen, Clin. Microbiol. Rev., 16, 37–64.
Nadelman, R. B., Horowitz, H. W., Hsieh, T.-C., Wu, J. M., Aguero-Rosenfeld, M. E., Schwartz, I., Nowakowski, J., Varde, S., and Wormser, G. P. (1997) Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis, N. Engl. J. Med., 337(1), 27–30.
Bakken, J. S., Krueth, J. K., Lund, T., Malkovitch, D., Asanovich, K., and Dumler, J. S. (1996) Exposure to deer blood may be the cause of human granulocytic ehrlichiosis [letter], Clin. Infect. Dis., 23, 198.
Walker, D. H. (2000) Diagnosing human ehrlichiosis: current status and recommendations, Am. Soc. Microbiol. News, 66, 287–291.
Masters, E. J., Olson, G. S., Weiner, S. J., and Paddock, C. D. (2003) Rocky Mountain spotted fever: a clinician’s dilemma, Arch. Intern. Med., 163, 769–774.
Horowitz, H. W., Kilchevsky, E., Haber, S., Aguero-Rosenfeld, M., Kranwinkel, R., James, E. K., Wong, S. J., Chu, F., Liveris, D., and Schwartz, I. (1998) Perinatal transmission of the agent of human granulocytic ehrlichiosis, N. Engl. J. Med., 339(6), 375–378.
Paddock, C. D., Sumner, J. W., Comer, J. A., Zaki, S. R., Goldsmith, C. S., Goddard, J., McLellan, S. L. F., Tamminga, C. L., and Ohl, C. A. (2004) Rickettsia parkeri: a newly recognized cause of spotted fever rickettsiosis in the United States, Clin. Infect. Dis., 38, 805–811.
Jones, T. E., Craig, A. S., Paddock, C. D., McKechnie, D. B., Childs, J. E., Zaki, S. R., and Schaffner, W. (1999) Family cluster of Rocky Mountain spotted fever, Clin. Infect. Dis., 28, 853–859.
Conlon, P. J., Procop, G. W., Fowler, V., Eloubeidi, M. A., Smith, S. R., and Sexton, D. J. (1996) Predictors of prognosis and risk of acute renal failure in patients with Rocky Mountain spotted fever, Am. J. Med., 101, 621–626.
Stallings, S. P. (2001) Rocky Mountain spotted fever and pregnancy: a case report and review of the literature, Obstet. Gynecol. Surv., 56, 37–42.
Buller, R. S., Arens, M., Hmiel, S. P., Paddock, C. D., Sumner, J. W., Rikihisa, Y., Univer, A., Gaudreault-Keener, M., Manian, F. A., Liddell, A. M., Schmulewitz, N., and Storch, G. A. (1999) Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis, N. Engl. J. Med., 341(3), 148–155.
Evans, M. E., Gregory, D. W., Schaffner, W., and McGee, Z. A. (1985) Tularemia: a 30-year experience with 88 cases, Medicine, 64, 251–269.
Cassady, K. A., Dalzell, A., Guffey, M. B., and Kelly, D. R. (2007) Ulceroglandular tularemia in a nonendemia area. (Disease/Disorder overview), South. Med. J., 100(3), 304–308.
Choi, E. (2002) Tularemia and Q fever, Med. Clin. North Am., 86, 393–416.
Hayes, E., Marshall, S., and Dennis, D. (2002) Tularemia: United States, 1990–2000, Morb. Mortal. Wkly Rep., 51, 182–184.
Enderlin, G., Morales, L., Jacobs, R. F., and Cross, J. T. (1994) Streptomycin and alternative agents for the treatment of tularemia: review of the literature, Clin. Infect. Dis., 19, 42–47.
Perez-Castrillon, J. L., Bachiller-Lique, P., Martin-Luquero, M., Mena-Martin, F. J., and Herreros, V. (2001) Tularemia epidemic in northwestern Spain: clinical description and therapeutic response, Clin. Infect. Dis., 33, 573–576.
James, A. M., Liveris, D., Wormser, G. P., Schwartz, I., Montecalvo, M. A., and Johnson, B. J. (2001) Borrelia lonestari infection after a bite by an Amblyomma americanum tick, J. Infect. Dis., 183, 1810–1814.
Burkot, T. R., Mullen, G. R., Anderson, R., Schneider, B. S., Happ, C. M., and Zeidner, N. S. (2001) Borrelia lonestari DNA in adult Amblyomma americanum ticks, Alabama, Emerg. Infect. Dis., 7, 471–473.
Homer, M. J., Aguilar-Delfin, I., Telford, S. R., Krause, P. J., and Persing, D. H., (2000) Babesiosis, Clin. Microbiol. Rev., 13, 451–469.
Boustani, M. R. and Gelfand, J. A. (1996) Babesiosis, Clin. Infect. Dis., 22, 611–615.
Krause, P. J. (2002) Babesiosis, Med. Clin. North Am., 86, 361–373.
Hatcher, J. C., Greenberg, P. D., Antique, J., and Jimenez-Lucho, V. E. (2001) Severe babesiosis in Long Island: review of 34 cases and their complications, Clin. Infect. Dis., 32, 1117–1125.
Krause, P. J., Lepore, T., Sikand, V. K., Gadbaw, J., Jr., Burke, G., Telford, S. R., 3rd, Brassard, P., Pearl, D., Azlanzadeh, J., Christianson, D., McGrath, D., and Spielman, A. (2000) Atovaquone and azithromycin for the treatment of babesiosis, N. Engl. J. Med., 343(20), 1454–1458.
Jacoby, G. A., Hunt, J. V., Kosinski, K. S., Demirjian, Z. N., Huggins, C., Etkind, P., Marcus, L. C., and Spielman, A. (1980) Treatment of transfusion-transmitted babesiosis by exchange transfusion, N. Engl. J. Med., 303(19), 1098–1100.
Dworkin, M. S., Schwan, T. G., and Anderson, D. E., Jr. (2002) Tick-borne relapsing fever in North America, Med. Clin. North Am., 86, 417–433.
Barbour, A. (1990) Antigenic variation of a relapsing fever Borrelia species, Annu. Rev. Microbiol., 44, 155–171.
Southern, P. M. and Sanford, J. P. (1969) Relapsing fever: a clinical and microbiological review, Medicine, 48, 129–149.
Dworkin, M. S., Anderson, D. E., Jr., Schwan, T. G., Schoemaker, P. C., Banerjee, S. N., Kassen, B. O., and Burgdorfer, W. (1998) Tick-borne relapsing fever in the northwestern United States and southwestern Canada, Clin. Infect. Dis., 26(1), 122–131.
Horton, J. M. and Blaser, M. J. (1985) The spectrum of relapsing fever in the Rocky Mountains, Arch. Intern. Med., 145, 871–875.
Cadavid, D. and Barbour, A. G. (1998) Neuroborreliosis during relapsing fever: review of the clinical manifestations, pathology, and treatment of infections in humans and experimental animals, Clin. Infect. Dis., 26, 151–164.
Negussie, Y., Remick, D. G., DeForge, L. E., Kunkel, S. L., Eynon, A., and Griffin, G. E., (1992) Detection of plasma tumor necrosis factor, interleukins 6 and 8, during the Jarisch-Herxheimer reaction of relapsing fever, J. Exp. Med., 175, 1207–1212.
Fekade, D., Knox, K., Hussein, K., Melka, A., Lalloo, D. G., Coxon, R. E., and Warrell, D. A. (1996) Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor, N. Engl. J. Med., 335(5), 311–315.
Teklu, B., Habte-Michael, A., Warrell, D. A., White, N. J., and Wright, D. J. (1983) Meptazinol diminishes the Jarisch-Herxheimer reaction of relapsing fever, Lancet, 1, 835–839.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Georgiev, V.S. (2009). Tick-Borne Bacterial, Rickettsial, Spirochetal, and Protozoal Diseases. In: Georgiev, V.S. (eds) National Institute of Allergy and Infectious Diseases, NIH. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-297-1_22
Download citation
DOI: https://doi.org/10.1007/978-1-60327-297-1_22
Publisher Name: Humana Press
Print ISBN: 978-1-60327-296-4
Online ISBN: 978-1-60327-297-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)